PMID- 18641415
OWN - NLM
STAT- MEDLINE
DCOM- 20081230
LR  - 20131121
IS  - 1939-4640 (Electronic)
IS  - 0196-3635 (Linking)
VI  - 29
IP  - 6
DP  - 2008 Nov-Dec
TI  - Testosterone and erectile dysfunction.
PG  - 593-604
LID - 10.2164/jandrol.107.004630 [doi]
AB  - Aging is associated with a decline in several important health factors in men, 
      including libido. Serum testosterone concentrations also decrease with age, and 
      many age-related clinical features are closely associated with androgen 
      deficiency, including erectile function (ED). Approximately 70% of ED is of 
      organic origin, with the major risk factors being diabetes mellitus, 
      hypercholesterolemia, smoking and chronic medical illnesses. These are also 
      established risk factors for atherosclerosis, which is the predominant 
      predisposing factor of vasculogenic ED. The introduction of phosphodiasterase-5 
      (PDE-5) inhibitors for the treatment of ED made a significant impact both in 
      terms of clinical efficacy, and increasing the awareness of the condition. In 
      spite of this, some patients fail to respond to PDE-5 inhibitors alone. Both 
      animal and clinical studies indicate that testosterone therapy improves both 
      erectile function and the response to PDE-5 inhibitors in patients with ED and 
      hypogonadism. Indeed, interventional studies demonstrate that testosterone 
      replacement therapy improves erectile function in hypogonadal men who have 
      previously failed to respond to PDE-5 inhibitors alone. Furthermore, it has been 
      demonstrated that the full therapeutic potential of PDE5 inhibitors will only 
      become manifest in a eugonadal state. Recent studies have demonstrated a close 
      relationship between testosterone and ED and suggest that testosterone therapy 
      may be a valuable option for an increasing number of affected men. European 
      guidelines recommend that all men presenting with ED should have their 
      testosterone concentrations measured.
FAU - Yassin, Aksam A
AU  - Yassin AA
AD  - Clinic of Urology/Andrology, Segeberger Kliniken, Norderstedt-Hamburg, Germany. 
      yassin@t-online.de
FAU - Saad, Farid
AU  - Saad F
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20080717
PL  - United States
TA  - J Androl
JT  - Journal of andrology
JID - 8106453
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Aging/physiology
MH  - Animals
MH  - Erectile Dysfunction/drug therapy/*etiology
MH  - Humans
MH  - Male
MH  - Phosphodiesterase Inhibitors/therapeutic use
MH  - Testosterone/*blood
RF  - 150
EDAT- 2008/07/22 09:00
MHDA- 2008/12/31 09:00
CRDT- 2008/07/22 09:00
PHST- 2008/07/22 09:00 [pubmed]
PHST- 2008/12/31 09:00 [medline]
PHST- 2008/07/22 09:00 [entrez]
AID - jandrol.107.004630 [pii]
AID - 10.2164/jandrol.107.004630 [doi]
PST - ppublish
SO  - J Androl. 2008 Nov-Dec;29(6):593-604. doi: 10.2164/jandrol.107.004630. Epub 2008 
      Jul 17.